SUBCUTANEOUS DARATUMUMAB (DARA SC) + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: SAFETY RUN-IN RESULTS OF ANDROMEDA
		        
		        	EHA Library, GIAMPAOLO MERLINI, 
		        			                215618
		            		       
		    
				
			
		        ACTIVITY AND SAFETY OF DARATUMUMAB MONOTHERAY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA REQUIRING DIALYSIS: PRELIMINARY RESULTS OF A SPANISH, RETROSPECTIVE, MULTICENTER TRIAL
		        
		        	EHA Library, Maria Jose cejalvo, 
		        			                215633
		            		       
		    
				
			
		        A PHASE 1B STUDY USING THE COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASOME IN MULTIPLE MYELOMA PATIENTS PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS
		        
		        	EHA Library, Cristina Gasparetto, 
		        			                215629
		            		       
		    
				
			
		        RANDOMIZED CLINICAL TRIAL (RCT) REPRESENTATIVENESS & OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REAL WORLD (RW) PATIENTS: COMPARISON OF ASPIRE, TOURMALINE-MM1, POLLUX, & ELOQUENT RCTS
		        
		        	EHA Library, Dorothy Romanus, 
		        			                215636